Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amarillo Biosciences or ABI has reported that the enrollment for its Phase II trial had reached 40 patients, halfway towards the goal of enrolling 80 patients in a study testing low dose oral interferon alpha lozenges in HIV positive subjects with oral warts.
Subscribe to our email newsletter
If, as anticipated, ABI’s new study demonstrates the efficacy and safety of this treatment regimen, ABI intends to conduct a Phase III study before filing a marketing approval application for interferon alpha lozenges in the treatment of oral warts in HIV-positive patients.
In a related development, ABI announced that it has retained The Patient Recruiting Agency (TPRA) of Austin, Texas to accelerate enrollment in its Phase II clinical trial of oral warts in HIV positive patients. TPRA will design a multi-media campaign that will include print, television and Internet advertising, plus a grassroots awareness effort.